A new comparative study published in the journal Clinical Chemistry is highlighting significant challenges in the standardization of glycated albumin (GA) testing, a biomarker used to monitor glycemic status.
Researchers systematically evaluated how different analytical methods quantify GA and identified measurable discrepancies that could affect clinical comparability across laboratories.
GA is increasingly used alongside other glycemic markers, but the study notes that methodological heterogeneity—differences in analytical approaches and target measurands—continues to limit consistent interpretation of results.
Comparing three analytical approaches
The investigators compared a targeted bottom-up proteomics method (ID-LC-MS/MS), an enzymatic assay, and the Japan Society of Clinical Chemistry (JSCC) reference method. The analysis included 129 donor serum samples, as well as certified reference materials (JCCRM-611), allowing for cross-method evaluation under standardized conditions.
Across platforms, the optimized proteomics method showed strong correlation with both the enzymatic assay and the JSCC reference method, with a correlation coefficient of r = 0.986. However, researchers observed a “progressively increasing negative systematic bias” at higher GA concentrations.
According to the findings, this bias indicates that measurement approaches focused on the Lys-525 site may underestimate GA levels when concentrations increase.
Site-specific versus total glycation signals
The study also examined glycation kinetics at the Lys-525 site of albumin. Results showed that as overall GA concentration increased, the proportion of glycation detected at Lys-525 decreased relative to total glycated lysine residues.
This finding suggests that site-specific measurements may not fully capture biologically relevant GA changes, particularly at higher concentrations.
Implications for standardization
The authors conclude that a universally accepted definition of GA measurement is needed to reduce analytical variability across platforms. They propose that quantification based on total glycated lysine residues—aligned with the JSCC method—may provide better agreement with biologically relevant GA values than site-specific approaches.
The study emphasizes that further standardization efforts should prioritize consistent measurand definitions to improve accuracy and comparability in clinical glycemic assessment.
Note: This news summary was generated by AI based on a published press release, followed by a review from human editors.
